Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2009 1
2011 1
2012 1
2013 2
2014 1
2016 3
2017 6
2018 1
2019 2
2022 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ; EORTC-55994 Study Group. Aggarwal R, et al. J Clin Oncol. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. Epub 2024 Jan 23. J Clin Oncol. 2024. PMID: 38261983 Clinical Trial.
RECISTing the Temptation to Prematurely Stop Nivolumab.
Humeniuk MS, Armstrong AJ. Humeniuk MS, et al. Eur Urol. 2017 Sep;72(3):377-378. doi: 10.1016/j.eururo.2017.04.021. Epub 2017 Apr 25. Eur Urol. 2017. PMID: 28454661 No abstract available.
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC, Halabi S, Somarelli JA, Humeniuk M, Wu Y, Oyekunle T, Howard L, Huang J, Anand M, Davies C, Patel P, Staats J, Weinhold KJ, Harrison MR, Zhang T, George DJ, Armstrong AJ. Brown LC, et al. Among authors: humeniuk m. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):762-769. doi: 10.1038/s41391-022-00524-7. Epub 2022 Mar 15. Prostate Cancer Prostatic Dis. 2022. PMID: 35292724 Free PMC article. Clinical Trial.
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ. Humeniuk MS, et al. Prostate Cancer Prostatic Dis. 2018 Apr;21(1):92-99. doi: 10.1038/s41391-017-0017-6. Epub 2017 Dec 11. Prostate Cancer Prostatic Dis. 2018. PMID: 29230006
Outcomes of patients with POEMS syndrome treated initially with radiation.
Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Humeniuk MS, et al. Blood. 2013 Jul 4;122(1):68-73. doi: 10.1182/blood-2013-03-487025. Epub 2013 May 22. Blood. 2013. PMID: 23699599 Free PMC article.
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D. Armstrong AJ, et al. Among authors: humeniuk ms. Prostate. 2017 Mar;77(4):385-395. doi: 10.1002/pros.23277. Epub 2016 Nov 16. Prostate. 2017. PMID: 27862097 Free PMC article. Clinical Trial.
20 results